

Blood culture ID test, 6/13:96

BioFire Diagnostics has submitted to the FDA its FilmArray blood culture identification (BCID) panel. The panel received the CE Mark earlier this month.

The submission comes after completion of clinical trials for the FilmArray BCID panel, which provides automatic results for common infectious causes of sepsis. BioFire anticipates commercial release of the panel this summer, pending FDA clearance.

Through a procedure that requires only two to three minutes of hands-on time, the BCID panel simultaneously tests positive blood cultures for about 90 percent of the gram-positive bacteria, gram-negative bacteria, and yeast microbes that cause bloodstream infections.

In addition, the panel tests for common antimicrobial resistance genes associated with MRSA, VRE, and the newly emerging CRE.

[BioFire Diagnostics](#), 800-735-6544